SCHEDULE: Avoro Capital Advisors Boosts Arrowhead Stake

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a beneficial ownership of 9.64% in Arrowhead Pharmaceuticals, Inc., including shares issuable upon warrant exercise.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh (collectively, the 'Reporting Persons') have filed an amended Schedule 13G, reporting beneficial ownership of 13,823,383 shares of Arrowhead Pharmaceuticals, Inc. Common Stock.
• This holding represents 9.64% of the class of securities outstanding as of May 1, 2026.
• The reported shares include 2,467,828 shares of Common Stock issuable upon the exercise of warrants.
• The filing indicates that the securities were acquired and are held solely for investment purposes.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but not overwhelming stake taken by an investment advisor, suggesting confidence in the company's future prospects without immediate aggressive control intentions.

Positives

• Significant stake acquired by Avoro Capital Advisors LLC and Behzad Aghazadeh, indicating confidence in Arrowhead Pharmaceuticals.
• The stake includes potential future shares through warrant exercise, suggesting a long-term investment perspective.
• The reporting persons are investment advisors, implying a strategic and analytical approach to their investment.

Negatives

• The filing does not detail the specific cost basis or average purchase price of the acquired shares, limiting a direct assessment of immediate profitability.
• The exact timing and terms of the warrant exercises are not specified, leaving some uncertainty about the immediate conversion of these potential shares.

Risks

• Market volatility could impact the value of the investment, especially given the inclusion of shares from warrant exercises.
• Changes in Arrowhead Pharmaceuticals' business performance or strategic direction could affect the value of Avoro's stake.
• Regulatory changes impacting investment advisory firms or beneficial ownership reporting could affect the Reporting Persons.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Arrowhead Pharmaceuticals. It solely reports on the beneficial ownership of securities by Avoro Capital Advisors LLC and Behzad Aghazadeh.

Management Comments

• "The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment advisors, particularly those specializing in life sciences as Avoro Capital Advisors appears to be, often signal a belief in the target company's growth trajectory or undervalued potential within the biotechnology sector. This filing places Arrowhead Pharmaceuticals within the context of active institutional investment in the biopharmaceutical space.

Stakeholder Impact

• Shareholders: The increased stake by a significant investment advisor may be viewed positively, potentially signaling confidence and leading to increased investor interest. However, it also means a larger portion of the company is held by a single entity.
• Management: The filing does not indicate any intention to influence control, suggesting current management can continue with their strategic plans without immediate pressure from this reporting entity.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Avoro Capital Advisors LLC and Behzad Aghazadeh will continue to hold and manage their investment in Arrowhead Pharmaceuticals, Inc.
• The company, Arrowhead Pharmaceuticals, Inc., may continue its operations and strategic initiatives as previously disclosed in its other filings.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the increased stake by Avoro Capital Advisors suggests confidence, it is a passive investment disclosure (Schedule 13G) rather than an active activist filing. The 9.64% ownership, including potential shares from warrants, represents a significant position but does not inherently signal a need to buy or sell immediately without further information on Arrowhead Pharmaceuticals' operational performance or strategic catalysts.

Keywords

Arrowhead Pharmaceuticals, Avoro Capital Advisors, Schedule 13G, Beneficial Ownership, Warrants, Investment Advisory, Common Stock, SEC Filing